VioQuest Pharmaceuticals (VOQP) Stock Price, News & Analysis

Company Overview

VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products' lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VOQP Stock Analysis - Frequently Asked Questions

How do I buy shares of VioQuest Pharmaceuticals?

Shares of VOQP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:VOQP
• CUSIP: N/A
• CIK: N/A
• Web: www.vioquestpharm.com
• Phone: (612) 220-3237
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A